Abstract
Aims
The effect of HCV eradication following the use of direct-acting antiviral drugs (DAAs) on the glyco-metabolic control is unknown. Through a meta-analysis of available clinical studies, we investigated whether eradication of HCV infection with interferon-free DAAs is associated with improved glyco-metabolic control in diabetic patients.
Methods
We searched the PubMed, MEDLINE and Embase, up to 08th June 2018, for all studies evaluating whether eradication of HCV infection with DAAs is associated with changes in glycated haemoglobin (HbA1c) and fasting plasma glucose (FPG) levels from baseline in human subjects, without restrictions for study type and language. Data were independently extracted by two researchers using pre-specified forms. Random effects meta-analyses were conducted on HbA1c and FPG levels before/after HCV eradication.
Results
We found a significant mean reduction in HbA1c levels of − 0.45% (95% CI − 0.60 to − 0.30%; P < 0.001) and in FPG levels of − 22.03 mg/dL (95% CI − 41.61 to − 2.44 mg/dL; P = 0.03), with high heterogeneity between studies (χ2 = 20.4, P < 0.001, I2 = 80% and χ2 = 35.8, P = 0.001, I2 = 94%, respectively). The number of available manuscripts did not allow conducting a meta-regression to elucidate the role of sustained virological response and other confounders in determining the effect of direct-acting antiviral agents on HbA1c reduction.
Conclusions
We found a significant improvement in glyco-metabolic control after HCV eradication (in terms of glycated haemoglobin and fasting plasma glucose levels reduction) following direct-acting antiviral treatment in patients with established diabetes, including a consequent positive impact on anti-diabetic therapies.
Similar content being viewed by others
Abbreviations
- HCV:
-
Hepatitis C virus
- SVR:
-
Sustained virological response
- HbA1c:
-
Haemoglobin A1c, A1C, glycosylated haemoglobin, glycated haemoglobin, glycol-haemoglobin
- DAA:
-
Direct-acting antiviral
- IFN:
-
Interferon
- NOS:
-
Newcastle–Ottawa Scale
- CT:
-
Clinical trial
- FPG:
-
Fasting plasma glucose
- CI:
-
Confidence interval
References
World Health Organization. Hepatitis C. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed 2 Jun 2018
Lecube A, Hernández C, Genescà J, Simó R (2006) Glucose abnormalities in patients with hepatitis C virus infection: epidemiology and pathogenesis. Diabetes Care 29:1140–1149
Mason AL, Lau JY, Hoang N, Qian K, Alexander GJ, Xu L et al (1999) Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 29:328–333
Antonelli A, Ferrari SM, Giuggioli D, Di Domenicantonio A, Ruffilli I, Corrado A et al (2014) Hepatitis C virus infection and type 1 and type 2 diabetes mellitus. World J Diabetes 5:586–600
Naing C, Mak JW, Ahmed SI, Maung M (2012) Relationship between hepatitis C virus infection and type 2 diabetes mellitus: meta-analysis. World J Gastroenterol 18:1642–1651
Lai MS, Hsieh MS, Chiu YH, Chen TH (2006) Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis virus infection. Hepatology 43:1295–1302
Veldt BJ, Chen W, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP et al (2008) Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 47:1856–1862
Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y, Ide T et al (2004) Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 165:1499–1508
Parvaiz F, Manzoor S, Iqbal J, Sarkar-Dutta M, Imran M, Waris G (2015) Hepatitis C virus NS5A promotes insulin resistance through IRS-1 serine phosphorylation and increased gluconeogenesis. World J Gastroenterol 21:12361–12369
Shi H, Tzameli I, Bjørbaek C, Flier JS (2004) Suppressor of cytokine signaling 3 is a physiological regulator of adipocyte insulin signaling. J Biol Chem 279:34733–34740
Basaranoglu M, Basaranoglu G (2011) Pathophysiology of insulin resistance and steatosis in patients with chronic viral hepatitis. World J Gastroenterol 17:4055–4062
Parvaiz F, Manzoor S, Tariq H, Javed F, Fatima K, Qadri I (2011) Hepatitis C virus infection: molecular pathways to insulin resistance. Virol J 18:474
Lecube A, Hernández C, Genescà J, Simó R (2006) Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: a case-control study. Diabetes Care 29:1096–1101
Romero-Gómez M, Del Mar Viloria M, Andrade RJ, Salmerón J, Diago M, Fernández-Rodríguez CM et al (2005) Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 128:636–641
Poustchi H, Negro F, Hui J, Cua IH, Brandt LR, Kench JG et al (2008) Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol 48:28–34
Simó R, Lecube A, Genescà J, Esteban JI, Hernández C (2006) Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection. Diabetes Care 29:2462–2466
Delgado-Borrego A, Jordan SH, Negre B, Healey D, Lin W, Kamegaya Y (2010) Reduction of insulin resistance with effective clearance of hepatitis C infection: results from the HALT-C trial. Clin Gastroenterol Hepatol 8:458–462
Hum J, Jou JH, Green PK, Berry K, Lundblad J, Hettinger BD (2017) Improvement in glycemic control of type 2 diabetes after successful treatmen of hepatitis C virus. Diabetes Care 40:1173–1180
Ciancio A, Bosio R, Bo S, Pellegrini M, Sacco M, Vogliotti E et al (2018) Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents. J Med Virol 90:320–327
Chaudhury CS, Sheehan J, Chairez C, Akoth E, Gross C, Silk R et al (2017) No improvement in hemoglobin A1c following hepatitis C viral clearance in patients with and without HIV. J Infect Dis 217:47–50
Carvalho JR, Velosa J, Serejo F (2018) Lipids, glucose and iron metabolic alterations in chronic hepatitis C after viral eradication-comparison of the new direct-acting antiviral agents with the old regimens. Scand J Gastroenterol 20:1–7
Prospero international prospective register of systematic reviews. Available from: https://www.crd.york.ac.uk/PROSPERO/. Accessed 2 Jun 2018
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264–269
Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008–2012
Greenberg PD, Rosman AS, Eldeiry LS, Naqvi Z, Bräu N (2006) Decline in haemoglobin A1c values in diabetic patients receiving interferon-alpha and ribavirin for chronic hepatitis C. J Viral Hepat 13:613–617
Unnikrishnan R, Anjana RM, Mohan V (2012) Drugs affecting HbA1c levels. Indian J Endocrinol Metab 16:528–531
Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M et al The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available from http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 2 Jun 2018
Downs SH, Black N (1998) The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 52:377–384
AASLD-IDSA Recommendations for testing, management, and treating hepatitis C. Monitoring patients who are starting hepatitis C treatment, are on treatment, or have completed therapy. Available from https://www.hcvguidelines.org/sites/default/files/full-guidance-pdf/HCVGuidance_May_24_2018a.pdf. Accessed 2 Jun 2018
Burgess SV, Hussaini T, Yoshida EM (2016) Concordance of sustained virological response at weeks 4, 12 and 24 post-treatment of hepatitis c in the era of new oral direct-acting antivirals: A concise review. Ann Hepatol 15:154–159
Martinot-Peignoux M, Stern C, Maylin S, Ripault MP, Boyer N, Leclere L et al (2010) Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virological response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology 51:1122–1126
European Association for the Study of the Liver (2017) EASL recommendations on treatment of hepatitis C 2016. J Hepatol 66:153–194
Abdel Alem S, Elsharkawy A, Fouad R, Adel E, Abdellatif Z, Musa S et al (2017) Improvement of glycemic state among responders to sofosbuvir-based treatment regimens: single center experience. J Med Virol 89:2181–2187
Ikeda A, Ikeda K, Takai A, Takahashi K, Ueda Y, Marusawa H et al (2017) Hepatitis C treatment with sofosbuvir and ledipasvir accompanied by immediate improvement in hemoglobin A1c. Digestion 96:228–230
Beig J, Orr D, Harrison B, Gane E (2018) HCV eradication with new IFN free treatment improves metabolic profile in HCV-related liver transplant recipients. Liver Transpl. https://doi.org/10.1002/lt.25060
Dawood AA, Nooh MZ, Elgamal AA (2017) Factors associated with improved glycemic control by direct-acting antiviral agent treatment in Egyptian type 2 diabetes mellitus patients with chronic hepatitis C genotype 4. Diabetes Metab J 41:316–321
Fabrizio C, Procopio A, Scudeller L, Dell’Acqua R, Bruno G, Milano E (2017) HCV and diabetes: towards a ‘sustained’ glycaemic improvement after treatment with DAAs? Clin Microbiol Infect 23:342–343
Pashun RA, Shen NT, Jesudian A (2016) Markedly improved glycemic control in poorly controlled type 2 diabetes following direct acting antiviral treatment of genotype 1 hepatitis C. Case Rep Hepatol. 2016:7807921
Stine JG. Wynter JA, Niccum B, Kelly V, Caldwell SH, Shah NL (2017) Effect of treatment with direct acting antiviral on glycemic control in patients with diabetes mellitus and chronic hepatitis C. Ann Hepatol 16:215–220
Huang JF, Huang CF, Yeh ML, Dai CY, Hsieh MH, Yang JF et al (2017) The outcomes of glucose abnormalities in chronic hepatitis C patients receiving interferon-free direct antiviral agents. J Med Sci 33:567–571
Lenters-Westra E, Schindhelm RK, Bilo HJ, Groenier KH, Slingerland RJ (2014) Differences in interpretation of haemoglobin A1c values among diabetes care professionals. Neth J Med 72:462–466
Funding
The financial support by the Agenzia Italiana del Farmaco (AIFA), by the Centre of Pharmacovigilance of Regione Lombardia (MEAP project, Monitoraggio degli Eventi Avversi nelle Popolazioni a Rischio, to EC), by the Italian Ministry of Health (RC 2017 to EC) and the Italian Ministry of Health (Ricerca Corrente 2018, to MP) is gratefully acknowledged. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author information
Authors and Affiliations
Contributions
CC and MP conceptualized and designed the study, carried out the data extraction and statistical analyses, drafted the manuscript and the summary tables, revised and approved the final manuscript as submitted. AD and FD contributed to literature extraction and manuscript revision and approved the final manuscript as submitted. MG and CM participated in the conceptualization and design of the study, participated in the analysis of the data, revised the article, and approved the final article as submitted. EC and SR participated in the conceptualization and design of the study, participated in the analysis and interpretation of the data, revised the article, and approved the final article as submitted. PF contributed to concept and design of the study, participated in the analysis and interpretation of the data, coordinated and supervised data collection, critically reviewed the manuscript and approved the final manuscript as submitted. PF is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Human and animal rights
This article does not contain any studies with human or animal subjects performed by the any of the authors.
Informed consent
For this type of study formal consent is not required.
Additional information
Managed by Massimo Federici.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Carnovale, C., Pozzi, M., Dassano, A. et al. The impact of a successful treatment of hepatitis C virus on glyco-metabolic control in diabetic patients: a systematic review and meta-analysis. Acta Diabetol 56, 341–354 (2019). https://doi.org/10.1007/s00592-018-1257-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00592-018-1257-1